Improve Research Reproducibility A Bio-protocol resource
- Protocols
- Articles and Issues
- For Authors
- About
- Become a Reviewer
Michael Peter Smith
Manchester Cancer Research Centre, Wellcome Trust Centre for Cell Matrix Research, Faculty of Life Sciences, The University of Manchester, UK
Personal information
Education
Ph.D. in Molecular Cancer Studies, University of Manchester, 2013
Current position
CRUK Research Associate, University of Manchester, Claudia Wellbrock Lab (2014-present)
Publications
-
Erice, O.*, Smith, M. P.*, White, R., Goicoechea, I., Barriuso, J., Jones, C., Margison, G. P., Acosta, J. C., Wellbrock, C. and Arozarena, I. (2015). MGMT expression predicts PARP-mediated resistance to temozolomide. Mol Cancer Ther 14(5): 1236-1246. (*Equal contribution)
-
Smith, M. P., Sanchez-Laorden, B., O'Brien, K., Brunton, H., Ferguson, J., Young, H., Dhomen, N., Flaherty, K. T., Frederick, D. T., Cooper, Z. A., Wargo, J. A., Marais, R. and Wellbrock, C. (2014). The immune microenvironment confers resistance to MAPK pathway inhibitors through macrophage-derived TNFalpha. Cancer Discov 4(10): 1214-1229.
-
Smith, M. P., Ferguson, J., Arozarena, I., Hayward, R., Marais, R., Chapman, A., Hurlstone, A. and Wellbrock, C. (2013). Effect of SMURF2 targeting on susceptibility to MEK inhibitors in melanoma. J Natl Cancer Inst 105(1): 33-46.